UBS lowered the firm’s price target on Occidental (OXY) to $45 from $46 and keeps a Neutral rating on the shares following the sale of OxyChem. While the debt reduction is the key positive, the transaction was dilutive across key metrics and valuation, the $8.3B Preferred Equity remains and limits shareholder returns, One Big Beautiful Bill tax benefits decline, and the comp to Large Cap peers is less attractive, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OXY:
- Occidental Petroleum’s Strategic Sale of OxyChem: Balancing Debt Reduction with Free Cash Flow Dilution
- Occidental upgraded to Outperform from Neutral at Mizuho
- Occidental upgraded to Buy from Hold at HSBC
- Occidental Petroleum’s Strategic Moves: Enhancing Shareholder Value through Divestment and Integration
- Morning Wrap-Up: Thursday’s Biggest Stock Market Stories!